Enteric coated risedronate 35mg for the treatment of osteoporosis

Description

In this Product Explainer, Endocrinologist Prof Ego Seeman explains the role of enteric coated risedronate 35mg for the treatment of osteoporosis (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Nicole Goh

A/Prof Nicole Goh

The NLCSP – Incidental Chest Findings – What Now? – A Focus on Interstitial Lung Abnormalities

A/Prof Mark Yates

A/Prof Mark Yates

Dementia & Chronic Disease – Practical Advice

Dr Julia Crawford

Dr Julia Crawford

Head and Neck Lumps

A/Prof Martin MacDonald

A/Prof Martin MacDonald

Why are LAMAs Useful in Asthma Management

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Ego Seeman

expert

Prof Ego Seeman

Endocrinologist; Dept of Medicine and Endocrinology, Austin Health, University of Melbourne; Editor, Progress in Osteoporosis

Date published: 7 November 2023